Benitec Biopharma Files 8-K on Security Holder Rights
Ticker: BNTC · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1808898
| Field | Detail |
|---|---|
| Company | Benitec Biopharma INC. (BNTC) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 B, $0 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing-update
TL;DR
Benitec Biopharma filed an 8-K today, watch for changes to shareholder rights and corporate structure.
AI Summary
On December 9, 2024, Benitec Biopharma Inc. filed an 8-K report detailing material modifications to security holder rights and amendments to its articles of incorporation or bylaws. The filing also includes financial statements and exhibits, indicating potential corporate restructuring or changes affecting its shareholders.
Why It Matters
This filing signals potential changes in the rights of Benitec Biopharma's security holders, which could impact their investment and the company's governance structure.
Risk Assessment
Risk Level: medium — Filings related to modifications of security holder rights and amendments to corporate governance documents can introduce uncertainty and potential risks for investors.
Key Players & Entities
- Benitec Biopharma Inc. (company) — Registrant
- December 9, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-39267 (other) — Commission File Number
- 3940 Trust Way, Hayward, California 94545 (address) — Principal Executive Offices
- (510) 780-0819 (phone_number) — Registrant's Telephone Number
FAQ
What specific material modifications were made to the rights of Benitec Biopharma Inc.'s security holders?
The filing indicates material modifications to the rights of security holders, but the specific details of these modifications are not provided in the summary text of the 8-K.
What are the key amendments to Benitec Biopharma Inc.'s articles of incorporation or bylaws?
The 8-K filing states that there were amendments to the articles of incorporation or bylaws, but the specific content of these amendments is not detailed in the provided text.
When was this 8-K report filed with the SEC?
This 8-K report was filed on December 10, 2024, with the earliest event reported being December 9, 2024.
What is Benitec Biopharma Inc.'s principal executive office address?
Benitec Biopharma Inc.'s principal executive office is located at 3940 Trust Way, Hayward, California 94545.
What is the SIC code for Benitec Biopharma Inc.?
The Standard Industrial Classification (SIC) code for Benitec Biopharma Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 613 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-12-10 17:00:29
Key Financial Figures
- $0.0001 B — ich registered Common Stock, par value $0.0001 BNTC The Nasdaq Stock Market LLC Indic
- $0 — 00 shares of preferred stock, par value $0.0001, and to make a corresponding chang
Filing Documents
- d919024d8k.htm (8-K) — 26KB
- d919024dex31.htm (EX-3.1) — 8KB
- 0001193125-24-274395.txt ( ) — 156KB
- bntc-20241209.xsd (EX-101.SCH) — 3KB
- bntc-20241209_lab.xml (EX-101.LAB) — 18KB
- bntc-20241209_pre.xml (EX-101.PRE) — 11KB
- d919024d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Benitec Biopharma Inc., effective December 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: December 10, 2024 By: /s/ Jerel A. Banks Name: Jerel A. Banks Title: Chief Executive Officer